[ad_1] GE Healthcare ‘s quiet outperformance is becoming harder to tune out — and its new…
Tag: Biogen Inc
5 things to know before the stock market opens Monday
[ad_1] Here are the most important news items that investors need to start their trading day:…
Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment
[ad_1] Hannah Yoon | The Washington Post | Getty Images Leqembi, an Alzheimer’s drug from Biogen…
Biogen beats expectations, hikes outlook as Alzheimer’s drug Leqembi and other new products gain traction
[ad_1] A test tube is seen in front of displayed Biogen logo in this illustration taken…
GEHC gives reasons to look beyond temporary China woes and shares reverse higher
[ad_1] GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply…
Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says
[ad_1] The newly FDA approved Alzheimer’s treatment Leqembi is prepared at Abington Neurological Associates in Abington,…
Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says
[ad_1] A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter…
European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
[ad_1] European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating…
Investors want proof AI will aid drug discovery. Evidence may come in the second half
[ad_1] As investors peer into the future to envision which industries are ripe to be reshaped…
FDA approval of Eli Lilly’s Alzheimer’s drug cements our decision not to take profits
[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable…
Biogen tops profit estimates as cost cuts take hold, Alzheimer’s drug Leqembi launch picks up
[ad_1] A test tube is seen in front of displayed Biogen logo in this illustration taken…
Sage Therapeutics stock plunges more than 50% after FDA denies wider use of postpartum depression drug
[ad_1] In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a…
These health-care companies see opportunity ahead from Alzheimer’s drug approval
[ad_1] As patients with Alzheimer’s disease seek out a newly approved treatment, they will need MRIs,…